Skip to main content
$1.24 $0.02 (1.6%)

08:00 PM EDT on 08/13/20

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX)

CAPS Rating: 2 out of 5

Current Price $1.24 Mkt Cap $110.2M
Open $0.00 P/E Ratio 0.00
Prev. Close $1.24 Div. (Yield) $0.00 (0.0%)
Daily Range $0.00 - $0.00 Volume 526
52-Wk Range $0.70 - $2.80 Avg. Daily Vol. 1,213,390

Caps

How do you think NASDAQ:ACRX will perform against the market?

Add Stock to CAPS Watchlist

All Players

60 Outperform
10 Underperform
 

All-Star Players

14 Outperform
6 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:ACRX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.20)
Submitted March 10, 2015

It looks like my reservations about AcelRx when the share price was 7 a few weeks ago were right, although the stock went on to a new six-month high over 9 just before the Sword of Damocles dropped. People or institutions who were buying AcelRx in… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:ACRX VS S&P 500 (SPY)

Fools bullish on NASDAQ:ACRX are also bullish on:

Fools bearish on NASDAQ:ACRX are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about ACRX.

Recs

0
Member Avatar tomfoolme (57.36) Submitted: 7/18/2020 12:01:12 PM : Outperform Start Price: $1.27 NASDAQ:ACRX Score: -6.86

AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. Its products include sufentanil, DZUVEO, DSUVIA ZALVISO US and ZALVISO EU 500% pain med
very low start point.

Recs

0
Member Avatar Bigsef77 (69.98) Submitted: 1/17/2019 1:15:21 PM : Outperform Start Price: $2.06 NASDAQ:ACRX Score: -65.26

Incredible Growth Story: AcelRx Pharmaceuticals, Inc. (ACRX)
By
Misty Lee -
January 17, 2019

B. Riley FBR rated the AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX)’s stock as a Buy in a research note published on Tuesday, October 23rd, 2018 and posted a $9 price target on the common stock of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Other Wall Street experts have also recently posted reports on these shares. RBC Capital Mkts gave the stock an Outperform rating, while setting a price target at $5 in a research note from Friday, October 13th, 2017. Jefferies rated the stock as a Hold in a research note dated Friday, October 13th, 2017.

At the moment, there are a total of 8 analysts who cover AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) stock. Among that group, 2 of them gave BUY ratings, 4 of them rated the stock as OUTPERFORM, 2 recommended it as HOLD, 0 set the rating at UNDERPERFORM and 0 rated it as a SELL. Looking at the big picture from the data above, the average analyst rating for AcelRx Pharmaceuticals, Inc. is 2.00.

The company, which is valued at $181.80M, last published its earnings results on Friday, 11/02/2018 for the quarter that ended in Sep-18. The business posted revenue of $0.38 million for the three-month period, below -$0.53 million, compared to analysts’ forecasts of $0.91 million with a surprise factor of 58.46%. The organization posted -$0.21 earnings per share (EPS) for the three-month period, surpassing the Thomson Reuter’s analyst consensus estimate of -$0.21 amounting to a surprise factor of -1.20%.

At times, the stock market can get highly confusing – even for some of the most experienced traders. Even when the result is what you had expected, the market might suddenly decide to make an opposing movement. This can spark a great deal of doubt and second-guessing. Keeping tabs on historical price performance, as well as both long-term and short-term trends, can be very useful. Over the past 7 days, AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) stock has decreased in price by 14.55%. Looking backwards over the past quarter, these shares have fell -45.22%. Turning to look at the last 6 months, this stock has dropped 24.19% to its price. Since the beginning of the calendar year, this stock has moved up by 9.30%.

Now let’s examine some potential support and resistance levels for this particular stock. Following a recent spotcheck, the public organization AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) has been observed as trading -53.47% away from its 90-day high price. Taking a look at the other side of things, this stock has been trading +18.09% away from its 90-day low. Moving to a broader perspective, this stock has recently been trading -53.47% away from its 52-week high and +42.42% away from its 52-week low price.

Recs

0
Member Avatar Speedylove (59.93) Submitted: 1/27/2016 4:46:27 PM : Outperform Start Price: $3.03 NASDAQ:ACRX Score: -123.65

Great new pain Mgmt platform

Leaderboard

Find the members with the highest scoring picks in ACRX.

Score Leader

brian3305

brian3305 (< 20) Score: +197.69

The Score Leader is the player with the highest score across all their picks in ACRX.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
brian3305 < 20 10/23/2012 Underperform 3M $3.14 -60.51% +137.18% +197.69 0 Comment
OriginalBarnacle 84.24 6/3/2013 7/1/2013 Underperform 1Y $9.10 -86.37% +105.37% +191.75 0 Comment
SaiyanBroker 90.73 3/15/2013 Underperform NS $4.65 -73.33% +115.98% +189.31 0 Comment
jackbot 92.66 7/28/2014 Underperform 5Y $6.45 -80.78% +69.94% +150.71 0 Comment
jasonrivera 75.02 1/13/2016 Underperform 5Y $3.05 -59.33% +77.80% +137.13 0 Comment
cashole 99.70 10/11/2018 Underperform 1Y $3.65 -66.03% +21.43% +87.46 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. gpierson128 99.11 1/14/2019 Underperform 5Y $2.61 -52.49% +30.99% +83.48 0 Comment
TheGreatSatan 99.99 3/27/2019 Underperform 5Y $3.18 -61.06% +19.69% +80.75 0 Comment
sikiliza < 20 9/6/2019 Underperform 5Y $2.39 -48.12% +12.83% +60.95 0 Comment
GirlsUnder30 29.76 8/13/2020 Underperform 5Y $1.25 -0.52% -0.34% +0.18 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for ACRX.